Literature DB >> 1157188

Structure and activity relationships of platinum complexes with anti-tumour activity.

P D Braddock, T A Connors, M Jones, A R Khokhar, D H Melzack, M L Tobe.   

Abstract

A number of complexes of platinum(II) and platinum(IV) have been prepared, characterised and tested for their ability to cause regression of a mouse plasma cell tumour. All active compounds possess two cis amine ligands but the oxidation state of the platinum is not critical. Relatively minor structural and substituent changes in the amine can lead to major and dramatic changes in the therapeutic index, generally, but not necessarily, associated with changes in toxicity. Some preliminary results on the relationship between structure and solubility are also reported.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1157188     DOI: 10.1016/0009-2797(75)90095-2

Source DB:  PubMed          Journal:  Chem Biol Interact        ISSN: 0009-2797            Impact factor:   5.192


  15 in total

1.  The cellular distribution and oxidation state of platinum(II) and platinum(IV) antitumour complexes in cancer cells.

Authors:  Matthew D Hall; Carolyn T Dillon; Mei Zhang; Philip Beale; Zhonghou Cai; Barry Lai; Anton P J Stampfl; Trevor W Hambley
Journal:  J Biol Inorg Chem       Date:  2003-07-12       Impact factor: 3.358

2.  Timely appraisal: ectopic (exocellular) nucleic acid as a drug target, especially in rheumatoid arthritis and certain cancers(?).

Authors:  M W Whitehouse
Journal:  Agents Actions       Date:  1975-12

3.  Interaction of platinum compounds with bacterial DNA.

Authors:  M Tamaro; S Venturini; C Eftimiadi; C Monti-Bragadin
Journal:  Experientia       Date:  1977-03-15

4.  Phase I--preliminary phase II trial of iproplatin, a cisplatin analogue.

Authors:  F P Paolozzi; R Gaver; B J Poiesz; A Louie; S DiFino; R L Comis; N Newman; S Ginsberg
Journal:  Invest New Drugs       Date:  1988-09       Impact factor: 3.850

5.  Retained platinum uptake and indifference to p53 status make novel transplatinum agents active in platinum-resistant cells compared to cisplatin and oxaliplatin.

Authors:  Robert F Murphy; Edina Komlodi-Pasztor; Robert Robey; Frank M Balis; Nicholas P Farrell; Tito Fojo
Journal:  Cell Cycle       Date:  2012-03-01       Impact factor: 4.534

6.  Modelling steric effects in DNA-binding platinum(II)-am(m)ine complexes.

Authors:  E Yuriev; J D Orbell
Journal:  J Comput Aided Mol Des       Date:  1996-12       Impact factor: 3.686

7.  Cisplatin Analogs Confer Protection against Cyanide Poisoning.

Authors:  Anjali K Nath; Xu Shi; Devin L Harrison; Jordan E Morningstar; Sari Mahon; Adriano Chan; Patrick Sips; Jangwoen Lee; Calum A MacRae; Gerry R Boss; Matthew Brenner; Robert E Gerszten; Randall T Peterson
Journal:  Cell Chem Biol       Date:  2017-04-13       Impact factor: 8.116

8.  Ammine/amine platinum (II) complexes effective in vivo against murine tumors sensitive or resistant to cisplatin and tetraplatin.

Authors:  Z H Siddik; G Thai; M Yoshida; Y P Zhang; A R Khokhar
Journal:  J Cancer Res Clin Oncol       Date:  1994       Impact factor: 4.553

Review 9.  Unusual DNA binding modes for metal anticancer complexes.

Authors:  Ana M Pizarro; Peter J Sadler
Journal:  Biochimie       Date:  2009-04-01       Impact factor: 4.079

Review 10.  Advances in platinum cancer chemotherapy. Advances in the design of cisplatin analogues.

Authors:  P C Hydes; M J Russell
Journal:  Cancer Metastasis Rev       Date:  1988-04       Impact factor: 9.264

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.